Gaming and Leisure Properties Inc. Common Stock vs Novavax Inc — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.11B), while Novavax Inc trades at $12.39 (market cap $2.08B). The key difference: Gaming and Leisure Properties Inc. Common Stock is far larger — about 5.3× Novavax Inc's market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.59% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| GLPI | NVAX | |
|---|---|---|
Market Cap | $11.11B | $2.08B |
Volume | 2,244,030 | 8,501,139 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $12.82 |
52-Week Low | $37.59 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $19.17B | $1.66B |
Dividend Yield | 8.59% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →